4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Myotonic Dystrophy by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 37 ongoing clinical trials involving Myotonic Dystrophy
Of the 37 trials,14 trials are in Phase II/III
Furthermore, 8 trials are in Phase I/II

Number of ongoing Clinical Trials (for drugs) involving Myotonic Dystrophy by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Myotonic Dystrophy, a musculoskeletal disorder. The largest number of ongoing clinical trials for Myotonic Dystrophy is conducted in Europe. Asia-Pacific and North America are among some of the other prominent regions engaged in Myotonic Dystrophy-related drug trials.

Lupin Ltd: The leading ongoing Myotonic Dystrophy related clinical trial sponsor

Lupin Ltd is the top sponsor for Myotonic Dystrophy-related ongoing clinical trials.

AMO Pharma Ltd, Myogem Health Company SL, and Osaka University Hospital are among other notable clinical trial sponsors involved in Myotonic Dystrophy. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Myotonic Dystrophy

Mexiletine hydrochloride (Namuscla), and Acetaminophen and eperisone (Myosone Plus) are among the key marketed drugs involving Myotonic Dystrophy.

Acetaminophen and eperisone is a fixed dose combination. It functions via Prostaglandin G/H Synthase 1 (Cyclooxygenase 1 or COX1 or Prostaglandin Endoperoxide Synthase 1 or Prostaglandin H2 Synthase 1 or PTGS1 or EC 1.14.99.1) Inhibitor; Prostaglandin G/H Synthase 2 (Cyclooxygenase 2 or COX2 or Prostaglandin Endoperoxide Synthase 2 or PHS II or Prostaglandin H2 Synthase 2 or PTGS2 or EC 1.14.99.1) Inhibitor; Voltage Dependent Calcium Channel Blocker mechanism of action. Eperisone is an antispastic agent and paracetmol is an analgesic agent. It is formulated as film coated tablets for oral route of administration. It is indicated for the improvement of myotonic conditions caused by neck shoulder arm syndrome, scapulohumeral periarthritis and low back pain in adult patients only. Myosone Plus is marketed in India by Macleods Pharmaceuticals Ltd.

Mexiletine hydrochloride (Namuscla) is an anti-arrhythmic agent. It functions via Voltage Gated Sodium Channel (SCN) Blocker mechanism of action. Mexiletine hydrochloride is formulated as hard gelatin capsules for oral route of administration. Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders. Namuscla was first approved in 2018 and is marketed globally including the UK, France, and Germany by Lupin Ltd.